Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010.
C4 Therapeutics has dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for patients with RRMM.
Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to ...
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway” ...
In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...
Gossamer Bio has reported topline data from the Phase III PROSERA study evaluating seralutinib in patients with PAH.
Compass will now seek approval for COMP360 in TRD, which could become the first classic psychedelic to gain the FDA’s ...
Senti Biosciences has completed enrolment of patients in its Phase I clinical trial assessing SENTI-202 in adults with ...
Teva Pharmaceuticals and Sanofi’s monoclonal antibody (mAb) has shown durable clinical and endoscopic efficacy in a Phase IIb ...
The North Midlands CRDC has recruited its first patient, representing the UK’s initial participation in a clinical trial of ...
Prasad and Makary disagree that some may believe this move to just one pivotal trial shows the FDA relaxing its standards.
Roche's Gazyva could become the first drug to gain approval in membranous nephropathy, pending regulatory decisions from the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results